Cargando…

COVID-19 pandemic impact on alcoholic hepatitis healthcare utilisation

Detalles Bibliográficos
Autores principales:	Nedumannil, Leya, Cheema, Sukhdeep Steven, Vaz, Karl, Ma, Ronald, Jones, Daryl, Warrillow, Stephen, Grace, Josephine, Wong, Darren, Choy, Matthew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association for the Study of the Liver. Published by Elsevier B.V. 2022
Materias:	POSTER PRESENTATIONS: Thursday 23 June: Alcoholic liver disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252378/ http://dx.doi.org/10.1016/S0168-8278(22)00649-3

Ejemplares similares

Trends of alcohol-related liver disease hospitalisation during the COVID-19 pandemic
por: Ayonrinde, Oyekoya, et al.
Publicado: (2022)

Increased hospital admissions for alcohol-associated hepatitis during the COVID-19 pandemic in Alberta, Canada: a retrospective cohort study
por: Frolkis, Alexandra, et al.
Publicado: (2022)

Fortification of alcoholic beverages (12% v/v) with tea (Camellia sinensis) reduces harmful effects of alcohol ingestion and metabolism in mouse model
por: Ochanda, S O, et al.
Publicado: (2016)

Quality standards for the management of alcohol-related liver disease: consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology ARLD special interest group
por: Parker, Richard, et al.
Publicado: (2023)

Progressive alcohol‐related liver fibrosis is characterised by imbalanced collagen formation and degradation
por: Thiele, Maja, et al.
Publicado: (2021)

Patients with decompensated cirrhosis and liver transplant recipients demonstrate poor humoral and cellular immune response against COVID-19 vaccine
por: Kulkarni, Anand, et al.
Publicado: (2022)

COVID-19 vaccination in liver cirrhosis: safety and immune and clinical responses
por: Canha, Maria Ines, et al.
Publicado: (2022)

Humoral and cellular immunity after vaccination against SARS-CoV-2 is reduced in patients with chronic liver disease
por: Samer, Al-Dury, et al.
Publicado: (2022)

Presence of cirrhosis in chronic liver disease patients associates with a lower immune response to COVID-19 vaccines-a multicenter european study
por: Simão, André L., et al.
Publicado: (2022)

Heterologous SARS-CoV-2 vaccine triggers more humoral immune responses among patients with liver cirrhosis
por: Kaewdech, Apichat, et al.
Publicado: (2022)

Enhancing the cascade of hepatitis C care in community-recruited high-risk people who inject drugs during the COVID-19 pandemic: the Alexandros program
por: Sypsa, Vana, et al.
Publicado: (2022)

Knowledge, attitude and practice regarding COVID-19 vaccination among HCV infected patients in Georgia
por: Gulbiani, Lasha, et al.
Publicado: (2022)

mRNA COVID-19 vaccine effectiveness in liver transplant patients
por: Khan, Muhammad, et al.
Publicado: (2022)

Assessment of COVID-19 impact and response on hepatitis B virus and hepatitis C virus prevention and treatment from nationwide survey in Japan
por: Ashraf Hussain, Md Razeen, et al.
Publicado: (2022)

A novel prognostic model including liver function parameters accurately predicts 30-day mortality in patients admitted with COVID-19
por: Lee, David Uihwan, et al.
Publicado: (2022)

Effectiveness of mRNA vaccines in patients with cirrhosis with rising prevalence of SARS-CoV-2 delta variant
por: John, Binu, et al.
Publicado: (2022)

Prognostic value of liver function test for COVID-19 hospitalized patients with respiratory disease
por: Mateu, Carlos Alventosa, et al.
Publicado: (2022)

Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosis
por: John, Binu, et al.
Publicado: (2022)

Implementation of HCV screening in the 1969–1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy
por: D’Ambrosio, Roberta, et al.
Publicado: (2022)

No effect of HBsAg positivity on antibody response after COVID-19 vaccine
por: Jargalsaikhan, Ganbolor, et al.
Publicado: (2022)

Humoral, cellular, clinical responses and safety to SARS-CoV-2 messanger RNA vaccines in patients with compensated and decompensated cirrhosis: a long-term single center prospective study
por: Iavarone, Massimo, et al.
Publicado: (2022)

The prognostic implications of liver function test abnormalities in patients admitted to hospital with COVID-19
por: Cohen, Jason, et al.
Publicado: (2022)

Evaluation of immune response and disease flares in metobolic-associated fatty liver disease patients following SARS-CoV-2 vaccination: a prospective cohort study
por: Shi, Junping, et al.
Publicado: (2022)

Combined COVID-19 vaccination and HIV and hepatitis C virus screening intervention for high-risk populations at a mobile testing unit in Madrid, Spain
por: Valencia, Jorge, et al.
Publicado: (2022)

The impact of COVID-19 pandemic control measures on HCV treatment initiation in British Columbia, Canada
por: Janjua, Naveed, et al.
Publicado: (2022)

Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease
por: Younossi, Zobair, et al.
Publicado: (2022)

Association between immunosuppressants and poor antibody responses to inactivated SARS-CoV-2 vaccines in patients with autoimmune liver diseases
por: Li, Hu, et al.
Publicado: (2022)

Do patients who die from an alcohol-related condition ‘drift’ into areas of greater deprivation? Alcohol-related mortality and health selection theory in Scotland
por: Pulford, Andrew, et al.
Publicado: (2018)

Impact on Product Appeal of Labeling Wine and Beer With (a) Lower Strength Alcohol Verbal Descriptors and (b) Percent Alcohol by Volume (%ABV): An Experimental Study
por: Vasiljevic, Milica, et al.
Publicado: (2018)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) is associated with worse outcomes in patients hospitalised for COVID-19: a real-world analysis of a large population from the premier healthcare database
por: Tacke, Frank, et al.
Publicado: (2022)

Effect of glass markings on drinking rate in social alcohol drinkers
por: Troy, David M., et al.
Publicado: (2017)

Measurable effects of local alcohol licensing policies on population health in England
por: de Vocht, F, et al.
Publicado: (2016)

Does Alcohol Cue Inhibitory Control Training Survive a Context Shift?
por: Jones, Andrew, et al.
Publicado: (2020)

Alcohol increases circulatory disease mortality in Russia: acute and chronic effects or misattribution of cause?
por: Leon, David A, et al.
Publicado: (2010)

Alcohol industry corporate social responsibility initiatives and harmful drinking: a systematic review
por: Mialon, Melissa, et al.
Publicado: (2018)

Failed Attempts to Improve the Reliability of the Alcohol Visual Probe Task Following Empirical Recommendations
por: Jones, Andrew, et al.
Publicado: (2018)

Declared funding and authorship by alcohol industry actors in the scientific literature: a bibliometric study
por: Golder, Su, et al.
Publicado: (2020)

A comparative study of industry responses to government consultations about alcohol and gambling in the UK
por: Bhuptani, Saloni, et al.
Publicado: (2023)

Alcohol intake and dyslipidemia in male patients with hypertension and diabetes enrolled in a China multicenter registry
por: Ye, Xiao‐Fei, et al.
Publicado: (2023)

Support for evidence-based alcohol policy in Ireland: results from a representative household survey
por: Calnan, Susan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6lk8qd905v90ghudr6pe05dgvh